Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | GPR6 | P46095 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238926 | 0.97 | CAPN1 (0.49) | L3MBTL1CAPN1CTSSHSD17B10MAPT | |
| SCHEMBL7238735 | 0.93 | CAPN1 (0.53) | CAPN1CTSSHSD17B10TSHRKMT2A | |
| SCHEMBL7235830 | 0.89 | CAPN1 (0.56) | CAPN1CTSSHSD17B10TSHR | |
| SCHEMBL7235461 | 0.89 | CAPN1 (0.47) | CAPN1CTSSHSD17B10TSHR | |
| SCHEMBL7239256 | 0.88 | L3MBTL1 (0.50) | L3MBTL1CAPN1CTSSHSD17B10TSHR | |
| SCHEMBL7243415 | 0.88 | CAPN1 (0.47) | CAPN1CTSSHSD17B10TSHRMAPT | |
| SCHEMBL7239455 | 0.85 | CAPN1 (0.49) | CAPN1CTSSTSHRMAPTKMT2A | |
| SCHEMBL7235428 | 0.84 | CAPN1 (0.57) | CAPN1CTSSHSD17B10TSHRKMT2A | |
| SCHEMBL7235181 | 0.84 | CAPN1 (0.50) | L3MBTL1CAPN1CTSSHSD17B10MAPT | |
| SCHEMBL7238619 | 0.82 | L3MBTL1 (0.54) | L3MBTL1HSD17B10KMT2ASIGMAR1CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562827-B1 | For the treatment of diseases in which increased calpain activity occurs such as neurodegenerative diseases or neuronal damage are caused by ischemia, trauma or mass hemorrhages | ABBOTT LABORATORIES | 2003-05-13 | — | — | US | disclosed |